M. E. Cooper

3.8k total citations
52 papers, 3.0k citations indexed

About

M. E. Cooper is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Clinical Biochemistry. According to data from OpenAlex, M. E. Cooper has authored 52 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Endocrinology, Diabetes and Metabolism, 17 papers in Cardiology and Cardiovascular Medicine and 12 papers in Clinical Biochemistry. Recurrent topics in M. E. Cooper's work include Advanced Glycation End Products research (12 papers), Chronic Kidney Disease and Diabetes (9 papers) and Blood Pressure and Hypertension Studies (9 papers). M. E. Cooper is often cited by papers focused on Advanced Glycation End Products research (12 papers), Chronic Kidney Disease and Diabetes (9 papers) and Blood Pressure and Hypertension Studies (9 papers). M. E. Cooper collaborates with scholars based in Australia, United Kingdom and United States. M. E. Cooper's co-authors include George Jerums, Merlin C. Thomas, Wendy C. Burns, Terri J. Allen, Tina Soulis, Richard E. Gilbert, Sherif Youssef, Mark Woodward, John Chalmers and Anushka Patel and has published in prestigious journals such as Journal of Clinical Investigation, Diabetes and Kidney International.

In The Last Decade

M. E. Cooper

51 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. E. Cooper Australia 30 1.2k 827 743 583 512 52 3.0k
Christos Tikellis Australia 25 1.2k 1.0× 502 0.6× 1.3k 1.8× 318 0.5× 1.1k 2.1× 30 3.7k
Riccardo Candido Italy 28 1.3k 1.1× 578 0.7× 1.1k 1.4× 366 0.6× 1.1k 2.2× 120 3.5k
Tomohito Gohda Japan 32 799 0.7× 519 0.6× 389 0.5× 1.5k 2.5× 651 1.3× 127 3.1k
Maria Luiza Caramori United States 16 852 0.7× 345 0.4× 395 0.5× 1.3k 2.2× 555 1.1× 32 2.7k
Sianna Panagiotopoulos Australia 35 1.6k 1.3× 836 1.0× 843 1.1× 1.9k 3.3× 711 1.4× 81 4.2k
Lena M. Thorn Finland 33 1.7k 1.5× 183 0.2× 823 1.1× 954 1.6× 412 0.8× 87 3.6k
Gabriella Gruden Italy 39 1.0k 0.9× 300 0.4× 655 0.9× 1.1k 1.9× 1.3k 2.5× 117 4.1k
Yoon Sik Chang South Korea 37 538 0.5× 212 0.3× 441 0.6× 951 1.6× 1.1k 2.1× 94 3.8k
Kei Fukami Japan 35 1.3k 1.1× 2.0k 2.5× 547 0.7× 1.0k 1.8× 1.0k 2.0× 135 4.5k
Seiji Ueda Japan 39 1.1k 0.9× 1.4k 1.7× 1.3k 1.7× 936 1.6× 949 1.9× 93 4.9k

Countries citing papers authored by M. E. Cooper

Since Specialization
Citations

This map shows the geographic impact of M. E. Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. E. Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. E. Cooper more than expected).

Fields of papers citing papers by M. E. Cooper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. E. Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. E. Cooper. The network helps show where M. E. Cooper may publish in the future.

Co-authorship network of co-authors of M. E. Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of M. E. Cooper. A scholar is included among the top collaborators of M. E. Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. E. Cooper. M. E. Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Forbes, Josephine M., Jenny Söderlund, Felicia Y. T. Yap, et al.. (2011). Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes. Diabetologia. 54(5). 1032–1042. 39 indexed citations
2.
Zoungas, Sophia, John Chalmers, Toshiharu Ninomiya, et al.. (2011). Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 55(3). 636–643. 265 indexed citations
3.
Harcourt, Brooke E., Melinda T. Coughlan, Josefa Pete, et al.. (2010). Regulation of renal receptor for advanced glycation end products (RAGE) via paracrine estrogens. Obesity Research & Clinical Practice. 4. S7–S8. 1 indexed citations
4.
Ninomiya, Toshiharu, Sophia Zoungas, Bastiaan E. de Galan, et al.. (2009). THE FIXED COMBINATION OF PERINDOPRIL AND INDAPAMIDE HAS A GREATER EFFECT ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND ALBUMINURIA. Journal of Hypertension. 27. 1 indexed citations
5.
6.
Calkin, Anna C., Karin Jandeleit‐Dahm, Terri J. Allen, et al.. (2007). PPARs and Diabetes-Associated Atherosclerosis. Current Pharmaceutical Design. 13(26). 2736–2741. 6 indexed citations
7.
Lassila, Markus, Kei Fukami, Karin Jandeleit‐Dahm, et al.. (2007). Plasminogen activator inhibitor-1 production is pathogenetic in experimental murine diabetic renal disease. Diabetologia. 50(6). 1315–1326. 36 indexed citations
8.
Tikellis, Chris, M. E. Cooper, C. I. Johnston, et al.. (2006). Developmental expression of ACE2 in the SHR kidney: A role in hypertension?. Kidney International. 70(1). 34–41. 75 indexed citations
9.
Calkin, Anna C., M. E. Cooper, Karin Jandeleit‐Dahm, & Terri J. Allen. (2006). Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia. 49(4). 766–774. 65 indexed citations
10.
Tikellis, Chris, M. E. Cooper, & Merlin C. Thomas. (2005). Role of the renin–angiotensin system in the endocrine pancreas: Implications for the development of diabetes. The International Journal of Biochemistry & Cell Biology. 38(5-6). 737–751. 48 indexed citations
11.
Cooper, M. E. & Dudley Creagh. (2004). 9th International Symposium on Radiation Physics (ISRP-9) Preface. Radiation Physics and Chemistry. 71. 607–609. 1 indexed citations
12.
Mogensen, Carl Erik & M. E. Cooper. (2004). Diabetic renal disease: from recent studies to improved clinical practice. Diabetic Medicine. 21(1). 4–17. 36 indexed citations
13.
Jerums, G., Terri J. Allen, D. Campbell, et al.. (2004). Long‐term renoprotection by perindopril or nifedipine in non‐hypertensive patients with Type 2 diabetes and microalbuminuria. Diabetic Medicine. 21(11). 1192–1199. 22 indexed citations
14.
Twigg, Stephen M. & M. E. Cooper. (2004). The time has come to target connective tissue growth factor in diabetic complications. Diabetologia. 47(6). 965–8. 43 indexed citations
15.
16.
Davis, Belinda J., C. I. Johnston, Louise M. Burrell, et al.. (2003). Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia. 46(7). 961–971. 55 indexed citations
17.
Soulis, Tina, Stephen A. Sastra, Vicki Thallas, et al.. (1999). A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia. 42(4). 472–479. 41 indexed citations
18.
Roufail, Edward, Tina Soulis, Esper Boel, M. E. Cooper, & Sandra Rees. (1998). Depletion of nitric oxide synthase-containing neurons in the diabetic retina: reversal by aminoguanidine. Diabetologia. 41(12). 1419–1425. 55 indexed citations
19.
Rumble, Jonathan R., M. E. Cooper, Tina Soulis, et al.. (1997). Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products.. Journal of Clinical Investigation. 99(5). 1016–1027. 160 indexed citations
20.
Gilbert, Richard E., M. E. Cooper, P.G. McNally, et al.. (1994). Microalbuminuria: Prognostic and Therapeutic Implications in Diabetes Mellitus. Diabetic Medicine. 11(7). 636–645. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christos Tikellis Breakdown of academic impact, for papers by Riccardo Candido Breakdown of academic impact, for papers by Tomohito Gohda Breakdown of academic impact, for papers by Maria Luiza Caramori Breakdown of academic impact, for papers by Sianna Panagiotopoulos Breakdown of academic impact, for papers by Lena M. Thorn Breakdown of academic impact, for papers by Gabriella Gruden Breakdown of academic impact, for papers by Yoon Sik Chang Breakdown of academic impact, for papers by Kei Fukami Breakdown of academic impact, for papers by Seiji Ueda
Rankless by CCL
2026